Myota Raises $4.5M to Turn Prebiotic Science Into a B2B Ingredients Platform
The London startup is betting that clinical validation, not marketing, is what separates a real fibre ingredient from a commodity one — and it now has the capital to sell that thesis to food manufacturers across Europe and the US.
The Round at a Glance
Myota, a London-based gut-health company, has closed a $4.5 million Series A led by specialist food-tech investor PeakBridge, which backed the company at an earlier stage and is doubling down on its conviction in clinically validated fibre. The capital will fund three things at once: a dedicated B2B sales operation across Europe and the US, faster scale-up of Myota's direct-to-consumer business, and continued clinical research into its ingredient platform.
The raise comes as Myota's UK consumer business tripled to more than 60,000 customers last year, and as the company shifts its center of gravity toward supplying food and beverage manufacturers directly — moving from a supplement brand into an ingredients platform with claimable, trial-backed health benefits.
Key Takeaways
- Myota raised $4.5M in Series A funding led by PeakBridge to build a dedicated B2B ingredients sales team across Europe and the US.
- The company's patented multi-fibre blends are designed to reliably produce short-chain fatty acids across different gut microbiomes, unlike single-fibre commodity products.
- Clinical trials show its gut blend cut bloating and diarrhoea symptoms in 80% of users over four weeks, while its metabolic blend improved insulin sensitivity in 61%.
- Myota already supplies Joe & The Juice and an unnamed coffee alternative brand, with dairy, bakery, and beverage products in development.
- The deal reflects a broader pivot in specialist food-tech investing toward science-backed functional ingredients, accelerated by rising GLP-1 drug adoption and gut-health awareness.
Why Off-the-Shelf Fibre Falls Short
Most fibre supplements on the market lean on one or two commodity fibres and market them with broad, undifferentiated claims. Myota's pitch to both consumers and manufacturers is that this approach ignores basic biology: the same fibre ferments differently depending on an individual's gut microbiome, producing wildly different amounts of short-chain fatty acids — the metabolites that actually drive fibre's health benefits.
Myota, founded by computational biologist Thomas Gurry and operator Kat Stennett, built its platform by measuring how different microbiomes ferment different fibres, then engineering multi-fibre blends designed to perform consistently across that variability. The company says this lets it maximise short-chain fatty acid output while reducing the gastrointestinal discomfort that typically limits how much fibre people can tolerate at once.
"-We can measure how an individual's gut bacteria ferment different fibres, and use that to build blends that produce short-chain fatty acids reliably across very different microbiomes."
The Investment Case: Proof Over Marketing
For PeakBridge, the bet is less about fibre as a trend and more about clinical substantiation as a moat. The firm argues that regulatory scrutiny on health claims is only getting tighter in both Europe and the US, and that companies willing to invest early in randomized controlled trials will be able to compete on defensible outcomes rather than on shelf-price alone — a harder position for commodity-fibre competitors to match quickly.
That thesis is reinforced by a second demand driver: the rise of GLP-1 weight-loss medications, which has pushed fibre back into the spotlight as a complementary lever for satiety, gastrointestinal tolerability, and nutrient density in smaller portions. Myota's existing commercial traction — supply deals with Joe & The Juice and a coffee alternative brand, plus development work with dairy, bakery, and beverage manufacturers — suggests the ingredient-platform pivot already has real customer pull behind it, rather than being purely aspirational.
"Myota built and patented the science first, then validated the outcomes in clinical trials. We saw fibre becoming a pillar of modern nutrition five years ago."
Yoni Glickman — Managing Partner, PeakBridgeRelevance for Saudi Arabia and MENA
For the Saudi and wider Gulf food and beverage sector, Myota's raise is a useful signal rather than an immediate market event. GLP-1 drug adoption is rising across the region alongside growing consumer interest in gut and metabolic health, creating an opening for functional ingredients that can carry substantiated, rather than purely marketed, health claims — the same gap Myota is targeting in Europe and the US.
As Saudi F&B manufacturers look to differentiate in bakery, dairy, and beverage categories under Vision 2030's push for higher-value domestic production, clinically validated fibre platforms represent the kind of specialty ingredient technology that regional players may increasingly look to license, import, or partner around, rather than build in-house.
Editorial View
Myota's raise is modest in size but points to a broader shift in specialist food-tech investing: capital is increasingly rewarding ingredient platforms that can prove efficacy in gold-standard trials and still work at usable doses in everyday food and drink — a combination the company itself frames as rare. Whether Myota can convert that scientific edge into durable B2B contracts at scale, against a backdrop of long sales cycles and fragmented health-claim regulation, will determine whether this becomes a template other functional-ingredient startups can follow.
